Mersana Therapeutics was a clinical-stage biopharmaceutical company focused on next-generation antibody-drug conjugates (ADCs) for cancer treatment, using its proprietary Dolasynthen and Immunosynthen ADC platforms. The company developed Emi-Le (emiltatug ledadotin), targeting B7-H4, for triple-negative breast cancer and other rare cancers. Mersana was acquired by Day One Biopharmaceuticals in January 2026.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2016
Mar 2015
Jul 2012
Apr 2012
Oct 2008
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Global biosimulation software and services company accelerating drug development for 2,000+ bioph...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
